RBC keeps Abbott as a top pick

RBC Capital Markets analyst Phil Nalbone kept Abbott Laboratories at a top pick, average risk, rating after the company announced definitive agreement to acquire Kos Pharmaceuticals for $3.7 billion. Kos, with its lipid management products, is a good strategic fit for Abbott, according to the analyst. Shares of the Abbott Park, Ill.-based biopharmaceutical company were down 58 cents, or 1.21%, at $47.28. (NYSE: ABT)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.